In the open-label study, DMD patients received Satellos’ oral drug for an additional 11 months, following an earlier 28-day trial.
Key Points Interested in Satellos Bioscience Inc.? Here are five stocks we like better. Satellos Bioscience said its SAT-3247 ...
At Binghamton University, researchers were among the first to find ways to help patients with Duchenne muscular dystrophy ...
Recently listed, Satellos Bioscience Inc. MSLE on Wednesday reported six-month interim data from its ongoing TRAILHEAD study ...
Phase 3 EPIDYS MRI data quantify givinostat’s potential to preserve functional muscle tissue and reduce fat infiltration in patients with ...
Spot Biosystems, a gene therapy company pioneering a novel non-viral extracellular vesicle (EV) delivery platform for genetic ...
Grünenthal announced today that its investigational compound tegacorat (GRM-01) received Orphan Drug and Rare Pediatric Disease Designations from the US Food and Drug Administration ...
The most commonly diagnosed form of muscular dystrophy, Duchenne is a genetic disease that affects mostly boys and causes progressive muscle weakness over time. Its early physical signs tend to be ...
DUBLIN--(BUSINESS WIRE)--The "Duchenne Muscular Dystrophy - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering. This report delivers an in-depth understanding of ...
For one remarkable day, an 18-year-old facing a life-threatening illness got to trade doctor’s appointments for an up close ...
DUBLIN--(BUSINESS WIRE)--The "Duchenne Muscular Dystrophy - Epidemiology Forecast to 2030" drug pipelines has been added to ResearchAndMarkets.com's offering. This report delivers an in-depth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results